Abstract:Background: Pulmonary sarcomatoid carcinoma (PSC) is a rare subtype of non-small cell lung cancer (NSCLC), which is featured by low incidence, high malignancy rate, robust aggressive behavior and inferior prognosis. To date, there is no standardized treatment. The aim of this study is to better understand and accumulate more clinical experience of the disease by summarizing the clinicopathological features, diagnosis methods, therapeutic regimen and prognostic factors of PSC. Methods: A total of 39 patients with PSC who diagnosed and received treatment in Beijing Chest Hospital from December 2013 to December 2023 were retrospectively recruited, and information including demographic characteristics, clinicopathological features, tumor-node-metastasis (TNM) stage, diagnosis method and therapeutic regimen were carefully collected. Meanwhile, follow-up was conducted. Kaplan-Meier method was used to analyze the prognostic factors of the disease. Results: The PSC patients in this study ranged in age from 45 to 76 years old, including 35 males and 4 females. There were no specific clinical manifestations of PSC at initial diagnosis. Among the 39 patients, 20 underwent surgical resection and 19 received palliative chemoradiation or symptomatic supportive treatment. The 1-year and 5-year survival rates were 61.90% and 35.20% respectively. Univariate analysis indicated that family history of carcinoma, primary tumor site, TNM stage, lymph node metastasis, distant metastasis, whether or not received surgical resection, surgical method, treatment regimens, tumor tissue programmed cell death ligand 1 (PD-L1) expression ≥1% and mesenchymal-epithelial transition factor (MET) pathway abnormalities were correlated with the overall survival (OS) of patients (P<0.05). In the subsequent multivariate analysis, lymph node metastasis emerged as the only independent prognosticator in predicting inferior OS (P=0.037). Conclusions: PSC is rarely seen in clinical practice and commonly occurs in elder men with smoking history. Tumor tissue PD-L1 expression ≥1% and MET abnormalities may predict inferior prognosis of PSC and lymph node metastasis was determined as the independent prognosticator of PSC. Surgical resection along with adjuvant medical treatment is the cornerstone for early and locally advanced patients, and the clinical utility of molecular targeting therapy and immunotherapy in PSC needs to be further investigated.

CT Imaging Analysis of Lung Sarcomatoid Carcimoma Correlated with Pathological Findings

[CT Manifestations of Primary Hepatic Sarcoma].

CT Findings and Pathological Features of Pulmonary Sarcomatoid Carcinoma

Primary Hepatic Sarcomas: CT Findings

Radiological Analysis of Lung Sarcomatoid Carcimoma Correlated with Pathological Findings

CT Features of Sclerosing Pneumocytoma

Chest Radiograph and CT Diagnosis of Primary Pulmonary Sarcoma

CT Manifestations and Pathological Features of Primary Adrenocortical Carcinoma

Enhanced CT Manifestation of Lung Sarcomatoid Carcinoma;Analysis of 3 Cases

Identification of CT Features to Differentiate Pulmonary Sarcoma from Carcinoma

Solid-pseudopapillary tumor of pancreas:MSCT imaging features and correlation with pathological findings

18F-FDG PET/CT imaging in pulmonary sarcomatoid carcinoma

[Clinicopathological Characteristics and Prognosis Analysis of 39 Patients with Pulmonary Sarcomatoid Carcinoma]

Successful diagnosis of pulmonary artery sarcoma by contrast-enhanced computed tomography.

Genomic Origin and Immune-Related Status of Pulmonary Sarcomatoid Carcinoma.

Clinical analysis of 78 pulmonary sarcomatoid carcinomas with surgical treatment

Pancreatic Sarcomatoid Carcinoma: CT, MRI, and 18F-FDG PET/CT Features

Genomic origin and intratumor heterogeneity revealed by sequencing on carcinomatous and sarcomatous components of pulmonary sarcomatoid carcinoma

Analysis of Radiological Features Relative to Pathology in Pelvic Chondrosarcoma

Integrated molecular characterization reveals potential therapeutic strategies for pulmonary sarcomatoid carcinoma